The Virtual Screening and Molecular Docking Study of New Inhibitors for SARS-COV-2 Papain-Like Protease (PLpro)

Alev Arslantürk Bingül; Necmettin Pirinççioğlu

Makale detayları

The Virtual Screening and Molecular Docking Study of New Inhibitors for SARS-COV-2 Papain-Like Protease (PLpro)

Yazarlar:

Alev Arslantürk Bingül | Necmettin Pirinççioğlu

Yayıncı:

Ataturk University

Ana Başlıklar:

Hesaplamalı Kimya

Dergi:

Ata-Kimya Dergisi Vol.5 Issue 1, pp.28-37

Belge Tipi:

Makale

Yayın Tarihi:

5/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001348603

pISSN:

2822-3926

Anahtar kelimeler:

Özet:

 Although global human mobility has normalized after the COVID-19 pandemic, the disease remains a major threat due to the emergence of new variants, keeping it a key target for drug development. Considerable efforts have been put to understand the disease, to create treatment options, and ultimately to eradicate it. It has been shown that these viruses have the largest genome size among all known RNA viruses, with their genome consisting of an RNA strand enclosed in a protein coat. PLpro is an enzymatic protein which is necessary for the replication process of SARS-CoV-2 and during viral infection, it is essential in helping coronaviruses evade the hosts innate immune defense. Consequently, targeting PLpro in antiviral drug development could be an effective approach to inhibit viral replication and interfere with signaling pathways in infected cells. This study aims to provide new potential inhibitor candidates for PLpro PDB: 7LOS by molecular modelling study. A total of over 2 million molecules from ZINC15 database have been screened against PLpro by structure- based virtual screening, followed by molecular docking. The docking scores of the top five ligands were in the range of -81.57 kcalmol and -83.19 kcalmol, which were much better than that of co-crystallized ligand Y97 -58.25 kcalmol. The docking results indicated that ligands interact with the key residues Asp 164, Arg 166, and Glu167 in the active pocket of PLpro. H02 revealed some physicochemical properties as a potential hit according to the ADME results.

 Although global human mobility has normalized after the COVID-19 pandemic, the disease remains a major threat due to the emergence of new variants, keeping it a key target for drug development. Considerable efforts have been put to understand the disease, to create treatment options, and ultimately to eradicate it. It has been shown that these viruses have the largest genome size among all known RNA viruses, with their genome consisting of an RNA strand enclosed in a protein coat. PLpro is an enzymatic protein which is necessary for the replication process of SARS-CoV-2 and during viral infection, it is essential in helping coronaviruses evade the hosts innate immune defense. Consequently, targeting PLpro in antiviral drug development could be an effective approach to inhibit viral replication and interfere with signaling pathways in infected cells. This study aims to provide new potential inhibitor candidates for PLpro PDB: 7LOS by molecular modelling study. A total of over 2 million molecules from ZINC15 database have been screened against PLpro by structure- based virtual screening, followed by molecular docking. The docking scores of the top five ligands were in the range of -81.57 kcalmol and -83.19 kcalmol, which were much better than that of co-crystallized ligand Y97 -58.25 kcalmol. The docking results indicated that ligands interact with the key residues Asp 164, Arg 166, and Glu167 in the active pocket of PLpro. H02 revealed some physicochemical properties as a potential hit according to the ADME results.

 Although global human mobility has normalized after the COVID-19 pandemic, the disease remains a major threat due to the emergence of new variants, keeping it a key target for drug development. Considerable efforts have been put to understand the disease, to create treatment options, and ultimately to eradicate it. It has been shown that these viruses have the largest genome size among all known RNA viruses, with their genome consisting of an RNA strand enclosed in a protein coat. PLpro is an enzymatic protein which is necessary for the replication process of SARS-CoV-2 and during viral infection, it is essential in helping coronaviruses evade the hosts innate immune defense. Consequently, targeting PLpro in antiviral drug development could be an effective approach to inhibit viral replication and interfere with signaling pathways in infected cells. This study aims to provide new potential inhibitor candidates for PLpro PDB: 7LOS by molecular modelling study. A total of over 2 million molecules from ZINC15 database have been screened against PLpro by structure- based virtual screening, followed by molecular docking. The docking scores of the top five ligands were in the range of -81.57 kcalmol and -83.19 kcalmol, which were much better than that of co-crystallized ligand Y97 -58.25 kcalmol. The docking results indicated that ligands interact with the key residues Asp 164, Arg 166, and Glu167 in the active pocket of PLpro. H02 revealed some physicochemical properties as a potential hit according to the ADME results.

 COVID-19 salgını sonrasında küresel insan hareketliliği normale dönmüş olsa da, hastalık yeni varyantların ortaya çıkması nedeniyle büyük bir tehdit olmaya devam ediyor. Bu sebeple, hastalığı anlamak, tedavi seçenekleri oluşturmak ve nihayetinde ortadan kaldırmak için önemli çabalar sarf edilmektedir. Bu virüslerin, bilinen tüm RNA virüsleri arasında en büyük genom boyutuna sahip olduğu ve genomlarının bir protein kılıfı içinde bulunan bir RNA ipliğinden oluştuğu kanıtlanmıştır. PLpro, SARS-CoV-2nin replikasyon süreci için gerekli olan enzimatik bir proteinidir ve viral enfeksiyon sırasında koronavirüslerin konağın doğuştan gelen bağışıklık savunmasından kaçmasına yardımcı olmakta görevlidir. Sonuç olarak, antiviral ilaç geliştirmede PLproyu hedeflemek, viral replikasyonu inhibe etmek ve enfekte hücrelerdeki sinyal yollarına müdahale etmek için etkili bir yaklaşım olabilir. Bu çalışma, moleküler modelleme çalışmasıyla PLpro PDB: 7LOS için yeni potansiyel inhibitör adayları sağlamayı amaçlamaktadır. ZINC15 veritabanından 2 milyondan fazla molekül, yapı tabanlı sanal tarama ve ardından moleküler yerleştirme ile PLproya karşı tarandı. İlk beş ligandın yerleştirme puanları, eş-kristalize ligand Y97nin -58,25 kcalmol puanlarından çok daha iyi olan -81,57 kcalmol ve -83,19 kcalmol aralığındaydı. Yerleştirme sonuçları, ligandların PLpronun aktif cebindeki anahtar kalıntılarla Asp 164, Arg 166 ve Glu167 etkileşime girdiğini gösterdi. ADME sonuçlarına göre H02, potansiyel bir hedef olarak bazı fizikokimyasal özellikler ortaya koydu.

Makale detayları

The Virtual Screening and Molecular Docking Study of New Inhibitors for SARS-COV-2 Papain-Like Protease (PLpro)

Yazarlar:

Alev Arslantürk Bingül | Necmettin Pirinççioğlu

Yayıncı:

Ataturk University

Ana Başlıklar:

Hesaplamalı Kimya

Dergi:

Ata-Kimya Dergisi Vol.5 Issue 1, pp.28-37

Belge Tipi:

Makale

Yayın Tarihi:

5/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001348603

pISSN:

2822-3926

SARS-CoV-2

PLpro inhibitors

virtual screening

molecular docking

drug designSARS-CoV-2

PLpro inhibitörleri

sanal tarama

moleküler yerleştirme

ilaç tasarımı

Sayı

Makale detayları

Yazarlar: Alev Arslantürk Bingül | Necmettin Pirinççioğlu

Yayıncı: Ataturk University

Ana Başlıklar: Hesaplamalı Kimya

Dergi: Ata-Kimya Dergisi Vol.5 Issue 1, pp.28-37

Belge Tipi: Makale

Yayın Tarihi: 5/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001348603

pISSN: 2822-3926

Sayı

Yazarlar:

Alev Arslantürk Bingül | Necmettin Pirinççioğlu

Yayıncı:

Ataturk University

Ana Başlıklar:

Hesaplamalı Kimya

Dergi:

Ata-Kimya Dergisi Vol.5 Issue 1, pp.28-37

Belge Tipi:

Makale

Yayın Tarihi:

5/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001348603

pISSN:

2822-3926